Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: October 25, 2012
Context: This filing reports a share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share capital movements.
- Shares Purchased: 1,100,000 Ordinary Shares (25 pence each).
- Price Range: Highest 1,413 pence; Lowest 1,404 pence per share.
- Treasury Holdings (Settled): 511,890,427 shares (9.40% of total issued share capital).
- Treasury Holdings (Including Unsettled): 515,290,427 shares (10.44% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,933,417,734 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 1,100,000 shares on October 25, 2012. Consequently, the percentage of shares held in Treasury increased to 9.40% of issued capital and 10.44% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to hold the repurchased shares in Treasury. The announcement confirms compliance with the Financial Services Authority's Disclosure and Transparency Rules.
Risks/Contingencies: No specific risks or contingencies are detailed in this filing. The text explicitly states this announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (4,933,417,734) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the impact of the 10.44% Treasury holding on total voting rights.
- Review the remaining authorization for share buybacks under the May 3, 2012 shareholder mandate.
- Note that this filing contains no operational or financial performance data for the period.